Argenx SE stock (NL0010832176): pipeline progress and commercial ramp in focus for Brussels investors

Argenx SE remains an active player on Euronext Brussels as its autoimmune drug pipeline advances and Vyvgart commercialization expands. Recent trial updates and financial disclosures keep the focus on long-term growth prospects for investors in Belgium and beyond.

Argenx SE is drawing continued attention from investors on Euronext Brussels as the company advances its antibody-based pipeline for autoimmune diseases and expands the commercial rollout of its lead product Vyvgart. Recent company disclosures and regulatory filings highlight a growing revenue base from immunology therapies alongside substantial ongoing research and development spending, a combination that positions Argenx as one of the more closely watched biotech names for Belgian and international equity investors.

In its most recent annual reporting cycle for FY 2024, which was discussed in an investor presentation published on 02/27/2025, Argenx reported that revenue for the full year 2024 was generated primarily from sales of Vyvgart (efgartigimod) and related formulations used to treat generalized myasthenia gravis and other autoimmune indications, according to company materials as of 02/27/2025.Argenx investor relations as of 02/27/2025 The same disclosure emphasized that the company continues to operate with a net loss on an annual basis due to high levels of investment in late-stage clinical trials and commercial infrastructure, as documented in the FY 2024 financial discussion dated 02/27/2025.Argenx news overview as of 02/27/2025

As of: 27.05.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Argenx
• Sector/industry: Biotechnology - immunology
• Headquarters/country: Rotterdam, Netherlands
• Core markets: United States, European Union, Japan
• Key revenue drivers: Autoimmune disease therapies led by Vyvgart (efgartigimod)
• Home exchange/listing venue: Euronext Brussels (ARGX)
• Trading currency: EUR

Argenx SE: core business model

Argenx operates as a biotechnology company focused on discovering, developing, and commercializing antibody-based therapies for severe autoimmune diseases and select oncology indications, with its current business model centered on the clinical and commercial exploitation of FcRn-targeting and other immunology mechanisms, per company descriptions in the 2024 annual reporting cycle published 02/27/2025.Argenx financial information as of 02/27/2025 The firm collaborates with academic and research institutions through its Immunology Innovation Program, which sources novel targets and antibodies that can be advanced into clinical candidates, as outlined in corporate materials dated 02/27/2025.Argenx about page as of 02/27/2025

Rather than operating as a diversified pharmaceutical conglomerate, Argenx pursues a focused immunology strategy that emphasizes late-stage clinical development and commercialization of a concentrated set of products in indications with high unmet medical need, according to its pipeline overview and strategic presentations issued on 02/27/2025.Argenx pipeline as of 02/27/2025 This model leaves the company with significant exposure to a small number of key assets, but also offers the potential for meaningful revenue expansion if ongoing trials in additional indications such as immune thrombocytopenia and chronic inflammatory demyelinating polyneuropathy progress as planned, based on disclosures in late 2024 and early 2025 investor updates as of 02/27/2025.Argenx news overview as of 02/27/2025

Main revenue and product drivers for Argenx SE

According to the FY 2024 financial discussion released on 02/27/2025, Argenx generated the majority of its 2024 revenue from commercial sales of Vyvgart in generalized myasthenia gravis across the United States, Europe, and Japan, with additional contribution from license and collaboration revenue related to its antibody platform, as reported in the companys annual materials as of 02/27/2025.Argenx financial information as of 02/27/2025 The company also began to benefit from subcutaneous and newer formulations of efgartigimod in 2024, which are intended to support more flexible dosing in chronic autoimmune conditions, according to product portfolio descriptions dated 02/27/2025.Argenx science overview as of 02/27/2025

Beyond its lead product, Argenx maintains a diversified pipeline of investigational therapies targeting other immune-mediated diseases, though these assets remain in earlier stages of development and therefore do not yet contribute materially to revenue as of FY 2024, based on pipeline status disclosures from 02/27/2025.Argenx pipeline as of 02/27/2025 The commercial focus on Vyvgart means that near-term revenue growth is closely tied to continued uptake in approved indications and potential label expansions, a pattern highlighted in Argenx management commentary in presentations distributed on 02/27/2025.Argenx investor relations as of 02/27/2025

What banks and research houses say about Argenx SE

According to MarketScreener as of 05/27/2026, the consensus across analysts covering Argenx SE is oriented toward a positive long-term view on the companys autoimmune pipeline, with the average price target quoted in the low to mid triple digits in USD terms at that date, based on MarketScreener as of 05/27/2026.

Conclusion

For investors following Argenx SE on Euronext Brussels, the stock represents an exposure to a focused immunology strategy built around Vyvgart and a broader pipeline of antibody-based candidates for autoimmune diseases, as reflected in financial and pipeline disclosures published through 02/27/2025.Argenx investor relations as of 02/27/2025 The companys continued net losses highlight the capital-intensive nature of late-stage biotech development, but also underscore the scale of its ambitions in markets such as generalized myasthenia gravis and other immune-mediated conditions, based on its FY 2024 reporting as of 02/27/2025.Argenx financial information as of 02/27/2025 How effectively Argenx converts clinical progress into sustainable cash flow will likely remain the central question for Belgian and international shareholders watching the stock in the coming quarters.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.